12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Akorn, Merck sales and marketing update

Akorn will acquire U.S. rights to ophthalmic products AzaSite 1% azithromycin, Cosopt and Cosopt PF dorzolamide/timolol maleate from Merck's Inspire Pharmaceuticals Inc. subsidiary for $52.8 million in cash. Merck will supply the products to Akorn for two years. Akorn plans to start shipping Cosopt and Cosopt PF upon closing of the deal and...

Read the full 275 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >